In the news release, MolecuLight Announces FIPS 140-3 Validated Encryption for MolecuLightDX+, issued 10-Nov-2026 by MolecuLight Corp. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:

MolecuLight Announces FIPS 140-3 Validated Encryption for MolecuLightDX+

Independent validation confirms that the encryption module used in MolecuLightDX+ meets U.S. government security standards

PITTSBURGH, Nov. 10, 2026 /PRNewswire/ — MolecuLight today announced that the encryption module used in its MolecuLightDX+ wound imaging device has achieved Federal Information Processing Standard (FIPS) 140-3 validation. This milestone provides healthcare organizations with independent assurance that the module meets U.S. government security requirements for protecting sensitive information.

The encryption module was validated under the Cryptographic Module Validation Program (CMVP). Certificate #5533 was issued on September 28, 2026, following testing by an accredited independent laboratory and review through the CMVP.

FIPS 140-3 establishes security requirements for cryptographic modules used to protect sensitive information. Validation confirms that the module has undergone independent testing against defined government standards. For hospitals, health systems, and federal healthcare organizations, this provides an objective benchmark when evaluating the security of medical technology.

“Healthcare organizations need confidence in both the clinical capabilities of their technology and the safeguards protecting patient information,” said Anil Amlani, Chief Executive Officer of MolecuLight. “This validation reinforces our commitment to supporting secure wound imaging, giving customers independent assurance that our encryption meets recognized government standards.”

The same validated encryption module is used across all MolecuLightDX+ configurations, including standalone devices, Essential and Enterprise packages, and devices integrated with electronic medical records. This provides a consistent foundation for encryption across different clinical settings and documentation workflows.

The milestone further demonstrates MolecuLight’s commitment to pairing objective wound imaging with data security, supporting healthcare teams as they evaluate and implement technology for patient care.

For more information, view the NIST validation record.

About MolecuLight

MolecuLight is a privately held medical imaging company with a global footprint, dedicated to manufacturing and commercializing point-of-care wound imaging devices. Its FDA-cleared MolecuLight i:X® and DX® systems provide real-time detection of elevated bacterial burden and accurate digital wound measurement. MolecuLightDX+® additionally offers thermal imaging. The technologies’ effectiveness and clinical utility are supported by more than 115 peer-reviewed publications.

Correction: A correction has been made to the second paragraph to remove a portion of a sentence. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculight-announces-fips-140-3-validated-encryption-for-moleculightdx-302935171.html

SOURCE MolecuLight Corp.